Survival and glycemic control outcomes among patients with coexisting pancreatic cancer and diabetes mellitus

Nina J Karlin; Shailja B Amin; Heidi E Kosiorek; Matthew R Buras; Patricia M Verona; Curtiss B Cook

doi:10.4155/fsoa-2017-0144

Survival and glycemic control outcomes among patients with coexisting pancreatic cancer and diabetes mellitus

Future Sci OA. 2018 Feb 21;4(4):FSO291. doi: 10.4155/fsoa-2017-0144. eCollection 2018 Apr.

Authors

Nina J Karlin^{1

1}, Shailja B Amin^{1

1}, Heidi E Kosiorek^{2

2}, Matthew R Buras^{2

2}, Patricia M Verona^{3

3}, Curtiss B Cook^{4

4}

Affiliations

¹ Division of Hematology & Medical Oncology, Mayo Clinic Hospital, Phoenix, AZ 85054, USA.
² Biostatistics, Mayo Clinic, Scottsdale, AZ 85259, USA.
³ Department of Information Technology, Mayo Clinic Hospital, Phoenix, AZ 85054, USA.
⁴ Division of Endocrinology, Mayo Clinic, Scottsdale, AZ 85259, USA.

Abstract

Aim: We aimed to determine the effect of diabetes mellitus (DM) on survival in pancreatic cancer and effects of pancreatic cancer on glycemic control in DM.

Materials & methods: Patients with pancreatic cancer from 2007 to 2015, with and without DM, were matched 1:1. We compared characteristics between the groups and assessed 2-year survival with Kaplan-Meier analysis.

Results: In patients with DM, hemoglobin A_1c decreased significantly over time (p = 0.01). In survival analysis, 2-year overall survival estimates were 15% (95% CI: 8-24%) for DM patients versus 26% (95% CI: 17-36%) for non-DM patients (p = 0.55). The hazard ratio for matched pairs was 1.15 (95% CI: 0.75-1.77; p = 0.51).

Conclusion: DM did not decrease survival in pancreatic cancer. Pancreatic cancer did not affect glycemic control.

Keywords: CA 19-9; cancer; endocrinology; glycemic control; outcomes research; pancreas; survival; therapy.